FDA releases second Pfizer gene therapy from clinical hold, as hemophilia program gets OK to restart
The FDA has released a clinical hold on Pfizer and Sangamo’s hemophilia A gene therapy after ordering the companies to stop the trial last year due to concerns about blood clots.
Just a week after Pfizer announced the FDA had unleashed its gene therapy for Duchenne muscular dystrophy from a clinical hold — which was paused as one patient died and others experienced severe side effects — another one of its gene therapy programs has been given the green light to resume, Pfizer announced during its Q1 earnings call yesterday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.